Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Singapore council recommends commercialisation of IP (intellectual property):

This article was originally published in Clinica

Executive Summary

Singapore wants to capitalise on its strength as a leading intellectual property centre through an increase of spending on R&D to build up the republic's technological facilities. In its latest meeting with the Singapore economic development board (EDB), the international advisory council (IAC) advised that Singapore should commercialise and not only retain its intellectual assets. The suggested increase in spending is from the current 2% of GDP to at least 3% within the next 10 years. The aim is to attract more industry talent to the country and to become a leader in technological advancements.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT054822

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel